Bing L Li

7090834, Aug 15, 2006

Apr 10, 2000

09/546857

Brian C. Cunningham - San Mateo CA, US
Abraham M. de Vos - Oakland CA, US
Bing Li - Foster City CA, US

Genentech, Inc. - South San Francisco CA

C12N 15/16
A61K 38/18
C07H 21/04

424 851, 435 71, 435 72, 435 691, 435 694, 435325, 4352523, 43525411, 4353201, 530399, 436501, 536 235, 536 2351, 930120

The present invention provides VEGF variants having one or more amino acid mutations in the KDR and/or FLT-1 receptor binding domains in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.

7093207, Aug 15, 2006

Nov 17, 2003

10/715082

Po-Shou Liao - Keelung, TW
Benny Huang - Jhonghe, TW
Charles Lai - Taipei, TW
Jimmy Liao - Erlin Township, TW
Bing Li - Fremont CA, US
Peter Eldredge - Scotts Valley CA, US
Leslie F. Smith - Puyallup WA, US
Felix Lai - Jhongjheng District, TW
Sino Ho - Hsinchu, TW
Ellis E-Li Chang - Saratoga CA, US
Sandeep Bhagwat - Milpitas CA, US
Anthony Cheung - Milpitas CA, US
Michael J. Bellon - Gilroy CA, US

KLA-Tencor Technologies Corporation - Milpitas CA

G06F 17/50
G06F 12/00
G06F 19/00

716 1, 707203, 700121

An extensible data analysis system for analyzing integrated circuit fabrication data produced during integrated circuit fabrication, including an application tier that selectively runs analysis nodes. The application tier has an architecture for optionally including and excluding a desired selection of the analysis nodes. The application tier architecture allows the selection of the analysis nodes to be dynamically added by a user. A data access tier selectively runs data reader nodes. The data access tier has an architecture for optionally including and excluding a desired selection of the data reader nodes. The data reader nodes interpret a desired variety of data source files containing the integrated circuit fabrication data having different formats for access by the application tier. The data access tier architecture allows the selection of the data reader nodes to be dynamically added by the user.

8552002, Oct 8, 2013

Jun 23, 2005

11/570983

Qiang Ding - Beijing, CN
Nathanael Schiander Gray - Boston MA, US
Bing Li - Northborough MA, US
Yi Liu - San Diego CA, US
Taebo Sim - Seoul, KR
Tetsuo Uno - San Diego CA, US
Guobao Zhang - San Diego CA, US
Carole Pissot Soldermann - Village-Neuf, FR
Werner Breitenstein - Basel, CH
Guido Bold - Gipf-Oberfrick, CH
Giorgio Caravatti - Bottmingen, CH
Pascal Furet - Thann, FR
Vito Guagnano - Basel, CH
Marc Lang - Mulhouse, FR
Paul William Manley - Basel, CH
Joseph Schoepfer - Riehen, CH
Carsten Spanka - Lorrach, DE

Novartis AG - Basel
IRM LLC - Hamilton

A01N 43/54
C07D 239/02

514256, 544242, 544298, 544299, 544315, 544319

The invention relates to compounds of formula (I).

20060063203, Mar 23, 2006

Aug 16, 2005

11/204554

Brian Cunningham - San Mateo CA, US
Abraham de Vos - Oakland CA, US
Bing Li - Foster City CA, US

Genentech, Inc. - South San Francisco CA

G01N 33/53
C07H 21/04
C12P 21/06
C07K 14/475
A61K 38/18

435007100, 514012000, 530399000, 536023500, 435069100, 435320100, 435325000

The present invention provides VEGF variants having at least a single amino acid mutation in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.

20060269997, Nov 30, 2006

Mar 15, 2006

11/376990

Brian Cunningham - San Mateo CA, US
Abraham de Vos - Oakland CA, US
Bing Li - Foster City CA, US

Genentech, Inc. - South San Francisco CA

C07K 14/475
C07H 21/04
C12P 21/06

435069100, 435320100, 435325000, 530399000, 536023500

The present invention provides VEGF variants having at least a single amino acid mutation in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.

20070066800, Mar 22, 2007

Apr 29, 2004

10/556106

Sachdev Sidhu - San Francisco CA, US
Bing Li - Foster City CA, US

C07K 14/74
C07K 16/28
C07H 21/04
C12P 21/06

530350000, 536023500, 530388220, 435069100, 435358000, 435252330, 435254200

Peptides are provided that bind Apo-2L receptor molecules. These peptides can be used for example in methods where a modulation of the biological activities of Apo-2L and/or Apo-2L receptor molecules such as DR5 is desired.

20070142284, Jun 21, 2007

Sep 29, 2006

11/536897

Brian Cunningham - San Mateo CA, US
Abraham de Vos - Oakland CA, US
Bing Li - Foster City CA, US

Genentech, Inc. - South San Francisco CA

A61K 38/18
C07K 14/475
C07H 21/04
C12P 21/06

514012000, 530399000, 435069100, 435320100, 435325000, 536023500

The present invention provides VEGF variants having at least a single amino acid mutation in the native VEGF sequence and selective binding affinity for either the KDR receptor or the FLT-1 receptor. Methods of making the VEGF variants and methods of using the VEGF variants are also provided.

20080248037, Oct 9, 2008

Apr 4, 2005

11/547457

Bing Li - Foster City CA, US
Sachdev S. Sidhu - San Francisco CA, US

Genentech, Inc. - San Francisco CA

A61K 39/395
C07K 16/18
A61P 43/00

4241381, 5303871, 5303873, 4241721

The application provides antibodies which specifically bind to DR5 receptor. The anti-DR5 antibodies optionally contain CDR sequences identified using phage-display techniques. The DR5 antibodies can be used, for example, in methods where a modulation of the biological activities of Apo-2L and/or Apo-2L receptors is desired, including cancer and immune-related conditions.